Zobrazeno 1 - 10
of 33
pro vyhledávání: ''
Autor:
Lusine Tumyan, Daniel Schmolze, Joanne E. Mortimer, Daniel Abler, David A. Hormuth, Angela M. Jarrett, Vikram Adhikarla, Prativa Sahoo, Thomas E. Yankeelov, Russell C. Rockne
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d692269c2e8a618712ec30483dae71
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
Mel Fox, Gary C. Starling, Mian Su, Sonia Tanlimco, Debra Chao, Shiming Ye, Donghee Choi, Johnny Yin, Lisa Durkin, Patricia Culp, Yongke Zhang, Eric D. Hsi, Mien Sho, Han Kim
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family members are appealing therapeutic targets in oncology due to their aberran
Autor:
Roy Nitulescu, Tripthi Kamath, Marjolaine Gauthier-Loiselle, Annie Guerin, Anthony Masaquel, Kenneth More, Raluca Ionescu-Ittu, Nicholas Sicignano, Brian Barnett, Christopher Gallagher, Elizabeth Butts, Eric Q. Wu
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzu
Autor:
Wilma L. Lingle, Beiyun Chen, Michael F. Press, Howard M. Stern, Monica M. Reinholz, Mona Shing, Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Soonmyung Paik, Reid G. Meyer, Melanie Finnigan, Marc Buyse, JoAnne Zujewski, Ivonne Villalobos, Dennis J. Slamon, Chungyeul Kim, Anne E. Wiktor
Publikováno v:
Breast Cancer Research and Treatment
A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed o
Autor:
Tejal Patel, Donald W. Northfelt, S. P. Kahanic, Sandra X. Franco, Edith A. Perez, Ismael Ghanem-Cañete, Robert B. Jenkins, David B. Johnson, Frances M. Palmieri, Gerardo Colon-Otero, Ann E. McCullough, Alvaro Moreno-Aspitia, Shaker R. Dakhil, Richard J. Rodeheffer, Kathleen S. Tenner, Amylou C. Dueck
Publikováno v:
Breast Cancer Research and Treatment
Lapatinib adds to the efficacy of trastuzumab in preclinical models and also in the neo-adjuvant setting. This study assesses the safety and feasibility of adding lapatinib to paclitaxel and trastuzumab (THL) as part of the adjuvant therapy for HER2-
Autor:
Suhail M. Ali, Yuping Tan, Allan Lipton, Christian F. Singer, Jeffrey S. Larson, Thomas Sherwood, Reinhard Horvat, Gordon Parry, Mojgan Haddad, A. Paquet, Jeff Sperinde, Kim Leitzel, Yolanda Lie, Xueguang Jin, John Winslow, Ahmed Chenna, Weidong Huang, Yining Shi, Joyee Banerjee, Jodi Weidler, Jennifer W. Cook, Wolfgang J. Köstler, Michael Bates, Alicia Newton, Ali Mukherjee, Eva Marie Fuchs, Laurie Goodman, Christos J. Petropoulos, Stephen Williams
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trast
Autor:
Joanna Pikiel, Michelle DeSilvio, Piotr Potemski, Wolfgang Janni, Elżbieta Starosławska, Kathryn Jane Briggs, Christian Caglevic, Etienne Brain, Christos Papadimitriou, Tomasz Sarosiek, Boguslawa Karaszewska, Luca Marini, Christoph Salat
Publikováno v:
Breast Cancer Research and Treatment
Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelb
Autor:
Sven Wind, Lisa A. Carey, Susan Cleator, Tamas Hickish, Duncan Wheatley, Nan Lin, Richard Vinisko, Laurie Frakes, Martina Uttenreuther-Fischer, David S. Mendelson, Steve Kelly, Stephen Houston, Hilary Jones, Agustin A. Garcia, Eric P. Winer, Pamela N. Munster
Publikováno v:
Breast Cancer Research and Treatment
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.